Single-dose pharmacokinetics of atrasentan, an endothelin-a receptor antagonist

Journal of Clinical Pharmacology

Volumn 41, Issue 4, 2001, Pages 397-403

  Samara, E ^a   Dutta, S ^a   Cao, G ^a  

^a Bldg AP13A ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST;

ADULT; APOPTOSIS; ARTICLE; BLOOD VESSEL REACTIVITY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISULFIDE BOND; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HUMAN; MALE; MEDIATOR RELEASE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIN-1; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PLACEBOS; RECEPTORS, ENDOTHELIN;

EID: 0035066386     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010258     Document Type: Article

References (17)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
3. Chronic oral endothelin type A receptor antagonism in experimental heart failure
4. Endothelins as autocrine regulators of tumor cell growth
5. Endothelin attenuates apoptosis in human smooth muscle cells
6. Endothelin receptor antagonism
7. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats
8. Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model
9. A-selective receptor antagonist
10. Inhibition of tumor growth and angiogenesis by ABT-627, an endothelin receptor A antagonist, in ovarian carcinoma xenografts
11. A program package for simulation and parameter estimation in pharmacokinetic systems
12. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects
13. The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123
14. A placebo controlled phase II dose-ranging evaluation of an endothelin-A receptor antagonist for men with hormone refractory prostrate cancer and disease-related pain